Relapsed or Refractory Multiple Myeloma (RRMM) research hub
11 indexed studies · 2 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
Hungary · Spain · Czechia - recruitingPHASE1
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
This study is testing a new drug, APL-4098, alone and with other medicines, for adults with certain types of blood cancers like Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). Doctors want to see if it's safe, how well it's tolerated, and if it helps.
Australia · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This study is testing a new drug, SY-1425, for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers are looking at how well it works, especially for patients with specific genetic markers, and if it's safe when used alone or with other medicines.
France - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)
This study is testing a new medicine, luveltamab tazevibulin, for babies and children under 12 with a specific type of blood cancer called CBFA2T3::GLIS2 acute myeloid leukaemia (AML). Researchers want to see if it helps these children get better, if it's safe, and how it works in their bodies.
Spain · Denmark · Netherlands - recruitingPHASE3
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
This study is testing a new drug, ziftomenib, for a type of blood cancer called AML. It combines ziftomenib with standard treatments for patients who haven't had treatment before, aiming to see if it works better than usual care alone.
United States · Australia · Belgium - active not recruitingPHASE2
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
This study looks at a new way to treat acute myeloid leukaemia (AML) in people who can't have standard, strong chemotherapy. It tests if giving a common drug (Azacitidine) for 5 days instead of 7 days might cause fewer side effects while still working well.
Germany - active not recruitingPHASE2
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
This study is testing a new drug, RVU120, for people with certain types of blood cancer (AML or high-risk MDS) that have come back or are not getting better with usual treatments. It aims to see if the drug is safe and helps fight the cancer.
France · Italy · Poland - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment
This study is testing a new drug, S65487, with an existing drug, azacitidine, for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for patients who haven't had treatment before and can't have intensive chemotherapy. We want to check if it's safe and how well it works.
France · Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
This early-stage study in the UK is testing a new type of treatment called UniCAR02-T-CD123 for people with a blood cancer called Acute Myeloid Leukaemia (AML). It's the very first time this treatment is being given to people, to check if it's safe and how it works.
Germany · Netherlands - authorisedTherapeutic exploratory (Phase II)
Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)
This study is looking at a new way to prepare people with acute myeloid leukaemia (AML) for a stem cell transplant. It's testing a combination of medicines (Fludarabine and Treosulfan) to see if it's safe and effective for adults aged 40 to 65.
Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II study on Venetoclax (VEN) plus Decitabine (DEC) (VEN-DEC) for elderly (≥60 <75years) patients with newly diagnosed Acute Myeloid Leukemia (AML) elegible for allogeneic Stem Cell Transplantation (allo-SCT)
This study looks at a new treatment called Venetoclax plus Decitabine for older patients (60-74 years) with a type of blood cancer called Acute Myeloid Leukemia (AML). It aims to see if this treatment helps them get a stem cell transplant, which can be a cure for AML.
Italy